Recursion Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75629V1044
SecurityMX:RXRX / Recursion Pharmaceuticals, Inc.
InstitutionDavy Global Fund Management Ltd
Latest Disclosed Ownership2,557,403 shares
Latest Disclosed Value $ 7,851,227
Davy Global Fund Management Ltd reports 6.38% increase in ownership of RXRX / Recursion Pharmaceuticals, Inc.

On May 11, 2026 - Davy Global Fund Management Ltd filed a 13F-HR form disclosing ownership of 2,557,403 shares of Recursion Pharmaceuticals, Inc. (MX:RXRX) valued at $7,851,227 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 2,404,118 shares of Recursion Pharmaceuticals, Inc.. This represents a change in shares of 6.38% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 2,557,403 153,285 6.38 7,851 -20.15 0.5962
2026-02-12 2025-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 2,404,118 629,123 35.44 9,833 13.52 0.6784
2025-11-05 2025-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 1,774,995 863,910 94.82 8,662 87.87 0.5870
2025-08-01 2025-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 911,085 523,848 135.28 4,610 125.10 0.4099
2025-05-09 2025-03-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 387,237 186,767 93.16 2,048 51.14 0.2411
2025-02-12 2024-12-31 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 200,470 118,118 143.43 1,355 150.00 0.1601
2024-10-16 2024-09-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 82,352 42,101 104.60 543 80.07 0.0565
2024-07-29 2024-06-30 13F RECURSION PHARMACEUTICALS IN CL A 75629V104 40,251 40,251 302 0.0346
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.